Your browser doesn't support javascript.
loading
Electrophysiological Manifestations of Cardiac Amyloidosis: JACC: CardioOncology State-of-the-Art Review.
Hartnett, Jack; Jaber, Wael; Maurer, Matthew; Sperry, Brett; Hanna, Mazen; Collier, Patrick; Patel, Divyang R; Wazni, Oussama M; Donnellan, Eoin.
Afiliação
  • Hartnett J; Department of Medicine, Trinity College Dublin, Dublin, Ireland.
  • Jaber W; Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio, USA.
  • Maurer M; Clinical Cardiovascular Research Laboratory for the Elderly (CCRLE), Columbia University College of Physicians and Surgeons, New York, New York, USA.
  • Sperry B; Saint Luke's Mid America Heart Institute and the University of Kansas City-Missouri, Kansas City, Missouri, USA.
  • Hanna M; Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio, USA.
  • Collier P; Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio, USA.
  • Patel DR; Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio, USA.
  • Wazni OM; Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio, USA.
  • Donnellan E; Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio, USA.
JACC CardioOncol ; 3(4): 506-515, 2021 Oct.
Article em En | MEDLINE | ID: mdl-34729522
ABSTRACT
Cardiac amyloidosis (CA) is an infiltrative cardiomyopathy caused by the extracellular deposition of amyloid fibrils in the myocardium. Although cardiac amyloidosis patients primarily present with heart failure symptoms, arrhythmias and conduction system disease are frequently encountered. Atrial fibrillation (AF) is observed in up to 70% of patients at the time of diagnosis, and patients typically have controlled ventricular rates caused by concomitant conduction system disease. Thromboembolic risk is particularly high in patients with CA and AF, and left atrial thrombi have been observed even in the absence of clinically diagnosed AF. Atrioventricular nodal and infra-Hisian disease are common, and permanent pacemakers are frequently required. The use of implantable cardioverter-defibrillators in this population is controversial. This review summarizes the published data and therapeutic strategies surrounding arrhythmias and conduction system disease with the goal of aiding clinicians managing the clinical complexities of CA.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2021 Tipo de documento: Article